Search clinical trials for: Single dose unit

Total 215207 results

BioRestorative Therapies

Recruiting

A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)

Lumbar Disc Disease

United States
University of Texas Southwestern Medical Center

Recruiting

A Phase I Dose Escalation Study of Single Fraction Ablative Pre-operative Partial Breast (S-PBI) for Early Stage Breast Cancer

Breast Cancer

United States
Eyenovia Inc.

Recruiting

Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression

Myopia

United States
National Institute of Allergy and Infectious Diseases...

Not yet recruiting

Single-Dose Study to Evaluate the PKs of Pretomanid in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

Renal Impairment | Tuberculosis

United States
Rush University Medical Center

Recruiting

Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery

Open Posterior Thoracolumbar Spinal Fusion Procedure

United States
AbbVie

Recruiting

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumors Cancer

United States, Australia, Israel, Japan, Korea, Republic of, Puerto Rico, Spain, Taiwan, Canada, France, Belgium
Fusion Pharmaceuticals Inc.

Recruiting

A Phase 1/2 Study of [225Ac]-FPI-1434 Injection

Cervical Cancer | Breast Cancer | Ovarian Cancer | Endometrial Cancer | Uveal Melanoma | Adrenocortical Carcinoma | Advanced Solid Tumours | HER2-negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | Head and Neck Squamous Cell Carcinoma (HNSCC)

United States, Australia, Canada
University of California, Davis

Recruiting

TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant

Pain, Postoperative | Transplant;Failure,Kidney

United States
University of Leeds
Takeda; Cancer Research UK; Celgene

Recruiting

Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma (FiTNEss)

Multiple Myeloma

United Kingdom
Nabriva Therapeutics AG

Recruiting

PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age) (Pediatric_PK)

Pediatric ALL

United States
Swedish Medical Center

Recruiting

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion (BEAM)

Multiple Myeloma

United States
Viramal Limited
Simbec Research

Recruiting

Study to Investigate the Pharmacokinetics & Safety Following One Application of 3 Different Doses 0.5,0.75,& 1.25 gm,a Transdermal Estradiol Cream (VML-0203), in Comparison to a Single Dose of EstroGel 1.25 gm to Healthy Post-menopausal Women.

Menopause

United Kingdom
National Institutes of Health Clinical Center (CC)

Recruiting

A Single Dose of Pembrolizumab in HIV-Infected People

Human Immunodeficiency Virus

United States
Bausch Health Americas, Inc.

Recruiting

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

Psoriasis

United States
Hoffmann-La Roche

Recruiting

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Belgium, Australia, Denmark, Spain, Taiwan, France, Italy, United States, Canada, Czechia, New Zealand, Poland, Finland
Cellectar Biosciences, Inc.

Recruiting

Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (CLOVER-WaM)

Multiple Myeloma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Central Nervous System Lymphoma

United States, Australia, Czechia, Greece, Israel, Brazil, Finland, France, Spain, Turkey, United Kingdom
Krzysztof Bankiewicz
National Institute of Neurological Disorders and Stroke (NINDS); University...

Recruiting

A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients (AADC)

AADC Deficiency

United States
Lisette Nixon
Cancer Research UK

Recruiting

Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation (SCOPE2)

Oesophageal Cancer

United Kingdom
Mansoura University

Recruiting

Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration

Infertility

Egypt
Transdermal Delivery Solutions Corp
Advanced Therapies Centre, The London Clinic

Not yet recruiting

A Dose Ranging Study to Examine TDS-Testosterone 5% (PARC-T-D)

Hypogonadotropism

United Kingdom
Tampere University
Finnish Cultural Foundation; Sigrid Jusélius Foundation; Päivikki and Sakari... and other collaborators

Recruiting

HaemoDYNAMICs in Primary and Secondary Hypertension (DYNAMIC)

Renal Insufficiency | Aortic Stenosis | Primary Hypertension | Secondary Hypertension

Finland
Emergent BioSolutions
United States Department of Defense

Completed

A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes as a Single Dose Regimen to SARS-CoV-2 Uninfected Adults

SARS-CoV-2 Infection

United States
Regeneron Pharmaceuticals

Active, not recruiting

A Trial to Learn if Single Ascending Intravenous (IV) Doses of REGN7508 Are Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants

Healthy Volunteer

United Kingdom
Denali Therapeutics Inc.

Completed

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-DNL343 Following a Single Oral Dose in Healthy Male Participants

Healthy Volunteers

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Non-squamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Carcinoma, Non-squamous Non-small-cell Lung

Poland, Korea, Republic of, Ukraine, United States, Argentina, Australia, Austria, Canada, France, Japan, New Zealand, Romania, Russian Federation, Taiwan, Turkey, United Kingdom, Brazil, Colombia, Germany, Spain
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Completed

A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Belgium, Finland, Netherlands, Serbia, Sweden
National Cancer Institute (NCI)

Active, not recruiting

Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8 | Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8

United States, Canada, Guam
Hepion Pharmaceuticals, Inc.

Completed

Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects

NASH With Fibrosis

United Kingdom
Incyte Corporation

Completed

A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants

Healthy Participants

United Kingdom
National Cancer Institute (NCI)

Completed

The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females

Prostatic Neoplasms

United States
Albert Einstein College of Medicine

Active, not recruiting

A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer (PROSINT)

Prostate Cancer

United States
Pfizer
Pfizer

Completed

A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)

Sickle Cell Disease

United States
GlaxoSmithKline

Active, not recruiting

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM-3)

Multiple Myeloma

United States, Australia, Spain, Bulgaria, Poland, Belgium, France, Germany, Italy, Hungary, United Kingdom, Greece, Russian Federation, Brazil, China, Korea, Republic of, Japan, Canada, Netherlands
Amgen

Completed

Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity

Obesity

United States
Alexion Pharmaceuticals, Inc.
Celerion

Completed

Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants

Healthy

United Kingdom
Pfizer

Completed

A Preliminary Study to Evaluate PF-07264660 in Healthy Participants

Healthy

United States
Principia Biopharma, a Sanofi Company

Completed

A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)

Healthy Volunteers | Hepatic Function Abnormal

United States
Genmab
BioNTech SE

Active, not recruiting

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Cervical Cancer | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Solid Tumors | Endometrial Carcinoma | Urothelial Carcinoma

United States, Spain, Israel, Czechia, Georgia, Italy, Poland, Turkey, Hungary, Ukraine
Novavax

Completed

A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. (COVID-19)

COVID-19

United States
The Plastic Surgery Foundation

Completed

Surgical Site Infection and Antibiotic Use Study (ASSERT)

Surgical Site Infection | Breast Reconstruction | Antibiotic Use

United States
Nuvamid SA
Medpace, Inc.; Anapharm; LGD

Completed

Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants

Healthy Volunteers

United States
AstraZeneca

Active, not recruiting

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

Non-alcoholic Steatohepatitis (NASH)

United States
Genentech, Inc.

Active, not recruiting

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Advanced/Metastatic Tumors

Spain, United States, Korea, Republic of, Australia, France, Japan, Canada
Biogen

Completed

A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants (Mass Balance)

Healthy Volunteer

United States
Cidara Therapeutics Inc.

Completed

A Single Ascending Dose Study of CD101 IV in Healthy Subjects

Healthy

United States
Ology Bioservices
United States Department of Defense

Active, not recruiting

Single or Repeat Dose of G03-52-01 in Adult Subjects

Healthy | Botulinum Toxin

United States
National Cancer Institute (NCI)
AstraZeneca; NRG Oncology

Active, not recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Ovarian Undifferentiated Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian... and other conditions

United States, Canada, Korea, Republic of, Japan
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Respiratory Syncytial Virus (RSV)

United States
AstraZeneca

Completed

Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants

Idiopathic Pulmonary Fibrosis

United States
Pfizer

Active, not recruiting

PF-07104091 as a Single Agent and in Combination Therapy

Breast Cancer | Small Cell Lung Cancer | Ovarian Cancer

United States, China, Japan, Mexico, Bulgaria, Argentina

Search clinical trials for: Single dose unit

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations